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Three isomers of chloro-3-(2-pyridin-3-ylvinyl)-1H-indole were synthesized and tested as inhibitors of
human tryptophan 2,3-dioxygenase (hTDO). The crystal structures of two of them were solved by X-ray
diffraction. The solubility of the molecules also was determined experimentally. The molecular elec-
trostatic potentials and dipole moments of the three isomers were calculated by ab initio quantum
mechanics (HF/6-311G).
The single crystal X-ray analyses reveal non-planar structures. This non-coplanarity is retained during
docking of the compounds into a model of hTDO, the molecular target of this series. The position of the Cl
atom does not signiﬁcantly affect the electronic delocalization. Nevertheless, the position of the Cl atom
produces a local variation of bond lengths inducing different dipole moments for these isomers. Varia-
tions in dipole moments are consistent with the different melting points and crystal packings. Differ-
ences in aqueous solubilities are best explained by subtle changes in H-bonds resulting from different
accessibilities of the indole NH’s due to steric effects of the Cl substituent. The non-coplanarity plays an
important role in the crystalline packing of the molecules in contrast to the position of the Cl. This study
leads to a better understanding of the structural and electronic characteristics of this chemical series and
can potentially help to better understand their inhibitory activity.
 2012 Elsevier Masson SAS. All rights reserved.p.ac.be (L. Moineaux),
son SAS. All rights reserved.1. Introduction
The essential amino acid L-tryptophan (L-Trp) is required for the
biosynthesis of proteins and is a precursor for several biologically
L. Moineaux et al. / European Journal of Medicinal Chemistry 54 (2012) 95e10296important compounds, including 5-hydroxytryptamine (5-HT,
serotonin), kynurenic acid or nicotinamide [1e3]. Tryptophan
hydroxylase controls 5-HT synthesis in the brain. In fact, this
enzyme has a large capacity for processing its substrate, trypto-
phan, and it has been shown that higher brain tryptophan levels
cause an increase in the 5-HT levels in both whole-brain and brain
extracellular ﬂuid. Indeed, L-tryptophan may be used as an
antidepressant but its efﬁcacy is weak because of its rapid catab-
olism [4].
The L-kynurenine pathway is the major catabolic route of
L-tryptophan metabolism and the key controlling enzymes are
tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-
dioxygenase (IDO). Both are cytosolic heme dioxygenases that
catalyze the oxidative cleavage of the C2eC3 bond of the indole ring
of L-tryptophan. This reaction is the ﬁrst and rate-limiting step of
the kynurenine pathway of tryptophan catabolism, which eventu-
ally leads to the formation of nicotinamide dinucleotide (NADþ),
a process regarded as the primary biological function of TDO [5e8].
Although hTDO and hIDO catalyze the same reaction and share
relatively conserved active site regions, amino acid sequences do
not exhibit more than a 10% level of identity [9], their physiological
functions are distinct. TDO is homotetrameric and almost exclu-
sively found in the liver [10]. It is highly speciﬁc for L-tryptophan
and some of its derivatives substituted in the 5- and 6-positions of
the indole ring [11]. On the other hand, IDO is monomeric and
extrahepatic and shows activity toward a larger collection of
substrates, including serotonin, tryptamine, 5-hydroxytryptophan,
and melatonin. The two enzymes also have different inducers; IDO
is induced by inﬂammatory stimuli such as interferon-g, and TDO
by tryptophan, glucocorticoids, and kynurenine [7,12].
Kynurenine pathway metabolites have been implicated in
a number of diseases ranging from neurological disorders, such as
cerebral malaria and multiple sclerosis, to cataract formation
[13,14]. Recent ﬁndings have implicated IDO-mediated tryptophan
catabolism in immune tolerance, including immune suppression in
maternal fetal tolerance and the immune escape of cancers
[15e20].
While IDO is a well-established target for cancer immuno-
therapy [21e28], it was only recently reported that TDO is also
expressed in many tumor cells including melanoma, colorectal,
bladder, hepatic, breast and lung cancers in a murine model of
cancer [29]. This work demonstrated that TDO expression in
tumors has an effect similar to the expression of IDO, preventing
tumor rejection by locally degrading tryptophan. A recent study
conﬁrmed another important mechanism of TDO-mediated
tumoral immune suppression, namely the release of the
tryptophan catabolite kynurenine, which then binds to the aryl
hydrocarbon receptor (AHR) [30]. Recently, we contributed to
a study describing a small-molecule TDO inhibitor which enables
reversal of tumoral immune resistance in vivo [31]. These ﬁndings
underline the importance of the precise TDO catalytic mechanism
and fully justify the search for potent inhibitors.
Until recently, only a handful of compounds based on the indole
or b-carboline scaffolds were reported as exhibiting TDO inhibitory
activity [5,32e35]. Among these, ﬂuoroindoles (680C91 andFig. 1. a, Structures of the leads. 680C91: R ¼ pyrid-3-yl; 709W92: R ¼ pyrid-4-yl; b, general
isomer.709W92, Fig. 1) [5,34,35] belonging to the 3-(2-(pyridyl)ethenyl)
indole class described by the Wellcome group as combined TDO/5-
HT (serotonin) reuptake inhibitors for antidepressant therapy
seemed to be the most interesting hits. 680C91 is an excellent
in vitro inhibitor (Ki of around 30 nM) on liver-extracted TDO, and at
10 mM, has no activity on 5-HT reuptake, various 5-HT receptors,
IDO and monoamine oxidases A and B [35]. However, in vivo, the
compound has no pronounced effect on tryptophan levels in rat,
presumably because of bioavailability/metabolism problems
[31,36,37].
As part of our interest in the design and synthesis of original
TDO inhibitors [38], we describe in this paper the structure and
physico-chemical properties of three isomers of chloro-pyr-
idinylvinyl-1H-indole, conﬁrm they inhibit TDO and propose
a rationale for this inhibition by docking simulations.
2. Experimental section
2.1. Single X-ray diffraction
Crystals of all three ((E)-chloro-3-(2-pyridin-3-ylvinyl)-1
H-indoles) were obtained by slow evaporation of solutions of the
samples at room temperature. Only crystals of (1) and (3) allowed
good quality structure determination by crystallography. X-ray
measurements were performed on a Gemini Ultra R system
(4-circle kappa platform, Ruby CCD detector) using Mo Kl radiation
(l ¼ 0.71073 Å). After mounting and centering the single-crystal on
the diffractometer, cell parameters were estimated from a pre-
experiment run and full data sets were collected at room
temperature. Structures were solved by direct methods with the
SHELXS-97 program and then reﬁned on F2 using the SHELXL-97
software [39]. E-map provided positions for all non H-atoms. The
full-matrix least-squares reﬁnement was carried out on F2 using
anisotropic temperature factors for all non H-atoms. The H-atoms
were located from DF-maps, and then their positions were reﬁned
using a ridingmodel with isotropic thermal parameters taken as 1.2
times temperature factors for their parent-atoms. The ORTEPs of
these isomers were obtained by the PLATON [40] program.
The quality of the crystallographic data for 6-chloro-3-(2-
pyridin-3-ylvinyl)-1H-indole was too poor to allow a good struc-
ture determination.
Crystal data for (1): crystallization by slow evaporation from
a tolueneemethyl acetate solution (1:1). Crystal dimensions:
0,20  0,10  0,28 mm. Monoclinic C2/c, a ¼ 15.784(2) Å,
b ¼ 9.352(1) Å, c ¼ 17.080(2) Å, V ¼ 2492.3(5) Å, Z ¼ 8,
Dcalc ¼ 1.3576 g/cm3, m(Mo Kl) ¼ 0.288 mm1, F(000) ¼ 1056,
qmin ¼ 3.4 to qmax ¼ 27.9, R ¼ 0.0344, wR2 ¼ 0.072, observed data
(I > 2sI) ¼ 1257, total ¼ 2599, R(int) ¼ 0.035, S ¼ 0.793.
Crystal data for (3): crystallization by slow evaporation from
a tolueneeethyl acetate solution (1:1). Crystal dimensions:
0,20 0,40 0,35mm.TriclinicP1, a¼11.081(1)Å,b¼13.128(1)Å,
c ¼ 14.863(1) Å, V ¼ 1862.9(3) Å, Z ¼ 6 (3 molecules in the a.u.),
Dcalc ¼ 1.3623 g/cm3, m(Mo Kl) ¼ 0.289 mm1, F(000) ¼ 792,
qmin ¼ 3.3 to qmax ¼ 32.6, R ¼ 0.0636, wR2 ¼ 0.119, observed data
(I > 2sI) ¼ 4184, total ¼ 12,288, R(int) ¼ 0.05, S ¼ 0.845.synthetic procedure for chloro-pyridinylvinlyl-1H-indoles. (1), 5-Cl; (2), 6-Cl; (3), 7-Cl-
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In order to model the structure, geometry optimization was
performed at the rhf/6-311G level of theory using the Gaussian suite
of programs [41]. Molecular electrostatic potential (MEP), suppress
HOMOeLUMO topologies and energies, and dipole moment were
computed. Gaussview allowed the visualization of dipole moments,
suppress HOMOeLUMO topologies and MEPs.
2.3. Solubility evaluation
The solubility was evaluated using Multiscreen HTS-PCF ﬁlter
plates from Millipore according to a protocol adapted from the
Millipore application note (“Quantitative method to determine
drug aqueous solubility: optimization and correlation to standard
methods” Thomas Onofrey and Greg Kazan http://www.millipore.
com/techpublications/tech1/an1730en00) at pH 1.0 (HCl 0.1 M,
NaCl 20 mM), 7.4 (phosphate buffer 50 mM, NaCl 30 mM) and 9.0
(boric acid 0.1 M, NaCl 20 mM) and with a ﬁnal DMSO concentra-
tion of 2.5%. The ﬁltrate was analyzed using an Agilent 1100 Series
LC/MSD Trap system with UV detection at 254 nm equipped with
a C18 Zorbax SB column (100  3 mm; 3.5 mm) and following
a gradient (ﬂow rate: 0.5 mL min1) of acetonitrile in aqueous
acetic acid 0.1% (v/v) (gradient: from 5 to 95% of acetonitrile in
5 min, holding for 3 min, then reversing to 5% of acetonitrile in
0.1 min and holding for an additional 5.4 min).
2.4. IC50 determination on hTDO
Enzymatic assays were performed by measuring the rate of
kynurenine formation by a discontinuous colorimetric method. The
reactions were performed by adding 1.3 mM (100 ml) puriﬁed
human TDO (hTDO) in a reaction mixture (900 ml) containing
50 mM tris buffer pH 8.0, 20 mM ascorbic acid, 100 mg of Bovine
Liver catalase, 5 mM hemin, 10 mM methylene blue, 100 mM L-tryp-
tophan and different concentrations of potential inhibitors in
a range of 0e100 mM. The mixture was pre-incubated at 37 C for
10 min before addition of the enzyme. The reactions were stopped
after 5,10,15 or 20min by adding 40 ml of 30% trichloroacetic acid to
200 ml of the reaction mixture and further incubated at 65 C for
15 min to hydrolyze N-formylkynurenine into kynurenine. After
centrifugation at 19,300 g for 10 min, 100 ml of supernatant were
added to 100 ml of para-dimethylaminobenzaldehyde (Ehrlich’s
reagent) in a 96-well plate. A positive reaction yields a yellow
solution [42]. The amount of formed kynurenine was determined
spectrophotometrically at 480 nm. Data were analyzed with the1 2 3 4 5
0
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40
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100a
Fig. 2. Residual activity (%) of puriﬁed human TDO in presence of isomers (1) (a) and (2) b
section.GraphPadPrism 5.0 program [43]. All determinations were per-
formed in duplicate and the presented data are average values.
The solutions and dilutions of the different inhibitors were
prepared in 100% DMSO. The ﬁnal concentration of DMSO in the
assaymixturewas 5% and it was veriﬁed that this concentration did
not affect the enzymatic activity. The enzyme studied is
a recombinant form of human tryptophan 2,3-dioxygenase (hTDO)
produced in Escherichia coli and puriﬁed to homogeneity.
2.5. Molecular modeling
Sequence alignment between human TDO (obtained from the
Swiss-Prot database) [44] and Ralstonia metallidurans (rmTDO (PDB
code 2NOX)) [45] was performed using BLASTP [46e48]. Amodel of
human TDO was thus developed by in silico mutation of only a few
amino acids from rmTDO. To take into account protein ﬂexibility,
the resulting model was minimized using the MINIMIZE module
included in SYBYL 8.0 program [49].
Molecular modeling studies were carried out on a Linux work-
station. The compounds were built using the SKETCH module
implemented in SYBYL (version 8.0) [49]. Docking was performed
using the 3D coordinates of our humanized TDO model with the
help of the automated GOLD program [50] (active site deﬁnition:
residues within 10 Å around heme). In order to take protein ﬂexi-
bility into account, the enzymeeinhibitor complexes were opti-
mized using the MINIMIZE module. The minimization process uses
the Powell method with the Tripos force ﬁeld (dielectric constant
1r) to reach a ﬁnal convergence of 0.01 kcal mol1.
3. Results and discussion
3.1. Compound synthesis
The compounds were synthesized according to the procedure
described in Fig. 1 and detailed elsewhere [38].
3.2. IC50 determination on human TDO
IC50 values were determined for two isomers of chloro-3-(2-
pyridin-3-ylvinyl)-1H-indole on the puriﬁed human TDO. For
isomers (1) and (2), the IC50 values were 10  0.5 mM and
5  0.4 mM respectively (Fig. 2).
For isomer (3), concentrations higher than 50 mM could not be
obtained because of solubility problems so that it was not possible
to determine an IC50 value by the samemethod. Thus, a Ki valuewas
determined by varying the substrate and inhibitor concentrations2 3 4 5 6
0
20
40
60
80
100b
. The enzymatic assays were performed in duplicate as described in the Experimental
L. Moineaux et al. / European Journal of Medicinal Chemistry 54 (2012) 95e10298and ﬁtting the data to the HenrieMichaeliseMenten equation
(Fig. 3). This study showed that isomer (3) behaved as a competitive
inhibitor with a Ki value of 21  0.3 mM. On the basis of the same
data, the Km value was evaluated at 180  1.4 mM, in good agree-
ment with the value determined in the absence of inhibitor.
To compare with the other two isomers, an IC50 value was
calculated with the help of the Dixon equation [51] for competitive
inhibition (Equation (1)).
IC50 ¼ Ki

1þ s
Km

(1)
At a substrate concentration of 100 mM, the calculated IC50 is
32  0.02 mM. The inhibitory activity is thus lower than that of the
other two isomers. This is consistent with the docking analysis (see
Sec. 3.6).
The three isomers inhibited hTDO and the best inhibitory
activity was obtained with the chlorine atom in position 5 on the
indole ring (1). However, these isomers of the chloro-pyr-
idinylvinyl-1H-indole family do not exhibit better inhibitory
activities than the reference inhibitor 680C91 (IC50 near 1.3 mM).3.3. Molecular conformation
Only a very limited number of substituted vinyl-1H-indoles (e.g.
3-(20-nitrovinyl)indole (CSD code: GOJDUE), ethyl 3-(1H-indol-3-
yl)acrylate (CSD code: GUGLEA), 3-(3-indolyl)acrylamide (CSD
code: SUVYIR), or (E)-4-(3-indolylvinyl)-N-methylpyridinium
iodide (CSD code: TIKBEU and TIKBIY)) crystal structures have been
determined by crystallography. Efforts to obtain crystals of ﬂuoro-
substituted 3-(2-pyridin-3-ylvinyl)-1H-indole isomers, including
680C91 proved unsuccessful in our hands. In contrast, crystals of
chloro-substituted 3-(2-pyridin-3-ylvinyl)-1H-indoles could be
grown providing valuable structural information on this family of
compounds both in terms of in depth analysis of molecular
conformations and crystal packings but also serving as starting
point for geometry optimizations.
Fig. 4 shows the ORTEP diagram of 5- and 7-chloro-3-(2-
pyridin-3-ylvinyl)-1H-indole isomers ((1) and (3), respectively)
with the atom numbering scheme. There are threemolecules in the
asymmetric unit of (3) in contrast to (1).
Both compounds possess an E conﬁguration at the C(10)]C(11)
double bond. Unexpectedly, this study reveals a signiﬁcant devia-
tion from coplanarity. Indeed, the values of the dihedral angle
between the plane of the pyridine and that of the indole are:Fig. 3. Initial rate of L-Trp oxidation by puriﬁed hTDO in the presence of varying
concentrations of 7-chloro-3-(2-pyridin-3-ylvinyl)-1H-indole (3) and L-Trip. The
enzymatic assays were performed as described in the Experimental section.46.49(7) (1), 22.23(7) (3a), 19.01(5) (3b), and 17.17(5) (3c).
Table 1S gives values of selected bond lengths for the two isomers.
These geometries obtained by crystallography (crystal packing
effects) are retained in structures optimized by ab initio methods
(rhf/6-311G) (Table 1S, supplementary data and tables for this
paper are available from supplementary materials). Inﬂuence of the
position of the Cl atom in the two isomers is essentially limited to
the C(4)eC(5), C(5)eC(6) and C(6)eC(7) bond lengths. Optimiza-
tion of (3), starting from the three distinct conformers (a, b, c)
observed in the crystal structure converged to a unique structure.
3.4. Crystal packing and intermolecular interactions
The crystal packings of (1) and (3a, b, c) are essentially deter-
mined by two factors: p-stacking and hydrogen bonds (HB).
For both isomers (1) and (3), a strong HB links nitrogen (N30) of
pyridine (hydrogen bond acceptor, A) with the (N1eH1) of the
indole ring (H-bond donor, DH) of a symmetry-related molecule
(Fig. 5). The isomers (3a) and (3b) exhibit a weak HB between
nitrogen (N30) of the pyridine and the (C1eH1) of the indole ring
[53,54]. The total number (one DeH and one A per molecule) and
strength (reﬂected by d, Table 2S, [52]) of these H-bonds is similar
for both isomers. Geometrical parameters used to describe the
stacking interactions are deﬁned in Table 3S which lists the values
of these parameters for our 2 crystal structures.
The crystal packingmodes of compounds (1) and (3) are given in
Fig. 5. In the packing of compound (1), the 6-membered ring of the
indole interacts with the 5-membered ring of another indole
moiety by pep stacking interactions. There is an additional pep
interaction between the pyridine group and the indole ring. In
contrast, for compound (3), only the 6-membered rings of the
indoles interact.
It is tempting to compare the stabilizing effects of crystal
packing with experimental physico-chemical parameters of the
compounds, in particular melting points (mp) [55] and solubility.
Therefore, melting points were determined. The solubility was
evaluated using Multiscreen HTS-PCF ﬁlter plates from Millipore
(Table 1).
Indeed, several H-bond interactions in (3) are similar to those in
compound (1) but analysis of the crystal packing suggests that pep
interactions are stronger for (1). This is consistent with the melting
points of these compounds. Compound (1), in which there is
a better stabilization by p-stacking, has a higher mp (222e223 C)
than compound (3) (204e205 C) with weaker stacking interac-
tions and similar H-bonds. It can be anticipated that the crystal
packing of (2) would be closer to that of (3) than to that of (1).
Aqueous solubility of the compounds (Table 1) is related to both
the stability of the solid state packing and solvation effects. If one
refers to the stability of the solid solutes (similar H-bonds and
differences in p-interactions) used to explain the experimental
melting points, the solubilities of (1) and (3) cannot be easily
explained. Indeed, compound (1), with the stronger packing (and
higher mp), is also more soluble that (3) (23 mg/mL for (1)
compared to 2.3 mg/mL for (3) at pH 7.4). The lower solubilities (at
pH 7.4 and 9.0) must thus be explained by solvation effects. As
discussed further (point 3.5.2 MEP) the position of the chlorine
atom close to the indole NH limits access to the H-bond donor and
signiﬁcantly stabilizes interactions with water molecules. This
steric effect of the Cl atom, which affects aqueous solubility
(mediated by H-bonding to the indole NH) could also explain, in
part, the lower afﬁnity of (3) for TDO.
The solubility of this series of compounds is higher at low pH (a
20 fold increase of solubility of (1) between pH 7.4 and pH 1). This is
most probably explained by protonation of the pyridine ring at low
pH values.
Fig. 4. View of the crystal structure conformations (ORTEP diagram, 50% probability level) for compounds (1) [top] and (3) [bottom]. Numbering is the same for all the molecules.
There are three molecules (a, b, c) in the asymmetric unit of (3).
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3.5.1. Dipole moments
The molecular dipole moment is a measure of charge distribu-
tion in a molecule. The accuracy of the overall distribution of
electrons in a molecule is difﬁcult to quantify, since it involves all
the multipoles. From the present calculations, the total dipole
moment and orientation vectors calculated with the geometries
optimized at the rhf/6-311G level of theory are given in Table 1.
The variations in the dipole moments are consistent with the
different melting points of the solids and to some extent, with their
solubility. Correlation with the solubility is less clear, as already
noted by others [56].
The inﬂuence of the position of the Cl substituent on the
distribution of atomic charges is limited but nevertheless leads to
signiﬁcant variations in the molecular dipole moments (Fig. 6a,Table 1). Compounds (1) and (2) exhibit a molecular dipole
moments larger than that of compound (3).
This is in agreement with similar H-bond patterns (in the crystal
packing) but distinct orientations of the molecule (due to the pep
stacking of the rings) in the crystal.
3.5.2. Electrostatic potential around isolated molecules
In order to calculate themolecular electrostatic potentials (MEP)
of these molecules, the geometry of the systemwas ﬁrst optimized
at the rhf/6-311G level of theory. Secondly, mapping of the MEP
onto the molecular surface was performed with Gaussview. The
MEP maps (Fig. 4b) reveal that essentially all three non charged
molecules present similar topologies and charge distributions. All
three compounds are characterized by attractive (negative)
potentials (redeyellow) on the N atom of the pyridine and a posi-
tive potential (blue) on the NeH function of the indole ring. The Cl
Fig. 5. Views of the crystal packing of (1) [top] and (2) [bottom]. Two selected orientations of the cell are presented for each compound in order to better visualize both hydrogen
bonds (highlighted by dotted lines) and p-stacking interactions.
L. Moineaux et al. / European Journal of Medicinal Chemistry 54 (2012) 95e102100atom also contributes and generates some attractive potential but
to a much lesser extent than the nitrogen of the pyridine.
This topology is in agreement with the H-bonds determined in
the crystallographic structure. Indeed, the pyridine nitrogen (N30) is
an H-bond acceptor which corresponds to the basic (negative) site
in MEP and the (N1eH1) of the indole group is an H-bond donor
which corresponds to the most positive region of the MEP. Inter-
estingly, as already underlined in the discussion of aqueous solu-
bility of our series, the relative position of the chlorine substituent
has a direct effect (steric hindrance and ‘shading’) on the MEP and
in consequence on the ability of the three isomers to form H-bonds.Table 1
Physico-chemical parameters of (1), (2) and (3): experimental properties (melting
points and solubilities determined at 3 pH’s) and calculated (rhf/6-311G) electronic
properties (molecular dipole moment).
Compound (1) (2) (3)
Solubility (mg/mL)
pH 1 540.3 473.3 550.8
pH 7.4 23.0 22.3 2.3
pH 9 76.0 32.1 6.0
Molecular dipole
moment (D)
7.41 5.69 3.15
Orientation vector of
dipolar moment (x,y,z)
1.61; 7.18;
0.86
0.43; 5.61;
0.80
0.32; 2.93;
1.12
Melting point (C) 222e223 204e208 204e2053.6. Modeling and docking
The biological data and stereo-electronic properties derived
from our study of the title compounds were combined with dock-
ing simulations into the active site of TDO and proved useful to
better understand the TDO inhibitory activity of those molecules.
To date, only the 3-D coordinates of TDO from R. metallidurans
(rmTDO) (PDB code: 2NOX) [45] and Xanthomonas Campestris
(xcTDO) [9] (PDB code: 1YW0) have been experimentally obtained.
These two bacterial TDOs present high sequence similarities with
the human form (28e34%) and excellent identities in the catalytic
site area. Sequences of hTDO and rmTDO were aligned using the
BLASTP program [46e48], showing that amino acids essential to
the activity werewell preserved around the heme cofactor. Docking
of the three isomers in the active site was performed in the struc-
ture of humanized rmTDO (i.e.: hTDO residues were mutated in the
structure of rmTDO) using the GOLD program [50]. The results are
summarized in Fig. 7.
The geometries of the three isomers in the docking solutions are
consistent with the crystallographic structures. Indeed, the non-
coplanarity, and the trans conﬁguration observed in the crystallo-
graphic study of these compounds is retained in the docking.
Moreover, the essential binding points (HB interactions and p-
stacking interactions) are also observed between the inhibitors and
the active site residues of TDO, for example, the formation of H-
bonds between the eNH of indole and His 72 and between the
Fig. 6. Representation of selected electronic properties calculated (rhf/6-311G) on optimized geometries of (1) [left], (2) [middle] and (3) [right]: molecular dipole moments (a, top)
and MEP contours (range between 179 and 179 kcal/mol, b, bottom).
Fig. 7. (a, top), Sequence alignment used for modeling of hTDO: residues of catalytic
site area (4 Å, underlined), conserved residue (pink), similar residues (yellow) and
different residues (blue) and (b, bottom) docked structure of (1) (blue), (2) (green) and
(3) (pink) into the active site of rmTDO.
L. Moineaux et al. / European Journal of Medicinal Chemistry 54 (2012) 95e102 101nitrogen of pyridine and Thr 271. These hydrogen bonds are similar
to those observed in the crystallographic study performed on the
two (isolated) isomeric chloro-3-(2-pyridin-3-ylvinyl)-1H-indoles.
These molecules interact in the sameway as the reference inhibitor
(680C91) [38].
Based on the docking simulations, it is tempting to suggest that
the reduced inhibition of TDO by compound (3) is due to a signiﬁ-
cant displacement of this inhibitor, compared to molecules (1) and
(2) which overlap well. This displacement, induced by steric effects
caused by the Cl atom, could result in a less favorable HB interaction
with His 72. In addition, the signiﬁcantly reduced value of the
dipole moment of (3) versus (1) and (2) could also explain weaker
pep interactions within the active site of TDO and thus a reduced
afﬁnity for the enzyme. This is consistent with the IC50 analysis.4. Conclusions
In conclusion, the TDO inhibition potencies of three previously
synthesized isomers of chloro-3-(2-pyridin-3-ylvinyl)-1H-indole
were evaluated. The single-crystal X-ray analyses of two of them
revealed non-planar structures. This non-coplanarity is retained
during docking of the compounds into the active site of a model of
humanTDO. The position of the Cl atomdoes not signiﬁcantly affect
the electronic delocalization within the molecule but allows local
bond length variations and overall differences for the value and
orientation of the dipole moments. Variations in dipole moments
are consistent with different melting points and crystal packings.
Differences in aqueous solubilities are best explained by subtle
L. Moineaux et al. / European Journal of Medicinal Chemistry 54 (2012) 95e102102changes in H-bonds resulting from different accessibilities of the
indole NH due to the steric effects of the Cl substituent. Similarly,
differences in H-bonding to the His 72 residue of the active site of
TDO could, in part, explain the afﬁnities that were measured. This
study also leads to a better understanding of themechanism of TDO
inhibition by this chemical series from the structural and electronic
points of view and the results obtained with the chloro-(2-pyridin-
3-ylvinyl)-1H-indoles must now be extrapolated to the ﬂuoro
analogs of 680C91.
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